UBS AM’s Aclaris Therapeutics ACRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$22.4K Buy
+4,267
New +$24.4K ﹤0.01% 3619
2024
Q1
– Sell
-113,601
Closed -$119K – 2520
2023
Q4
$119K Hold
113,601
– – ﹤0.01% 2520
2023
Q3
$778K Buy
113,601
+25,585
+29% +$219K ﹤0.01% 2092
2023
Q2
$712K Hold
88,016
– – ﹤0.01% 2162
2023
Q1
$712K Hold
88,016
– – ﹤0.01% 2162
2022
Q4
$1.39M Buy
88,016
+1,310
+2% +$21.1K ﹤0.01% 1700
2022
Q3
$1.36M Buy
86,706
+439
+0.5% +$6.92K ﹤0.01% 1792
2022
Q2
$1.2M Buy
86,267
+36,921
+75% +$517K ﹤0.01% 1859
2022
Q1
$851K Hold
49,346
– – ﹤0.01% 2224
2021
Q4
$717K Buy
49,346
+12,880
+35% +$195K ﹤0.01% 2381
2021
Q3
$656K Buy
36,466
+5,186
+17% +$83.1K ﹤0.01% 2374
2021
Q2
$549K Buy
+31,280
New +$711K ﹤0.01% 2502
2019
Q2
– Sell
-11,368
Closed -$68.1K – 2856
2019
Q1
$68.1K Buy
+11,368
New +$75.4K ﹤0.01% 2592
2018
Q1
– Sell
-9,568
Closed -$236K – 2654
2017
Q4
$236K Sell
9,568
-224,028
-96% -$5.46M ﹤0.01% 2227
2017
Q3
$6.03M Buy
233,596
+123,559
+112% +$3.31M 0.01% 1027
2017
Q2
$2.98M Buy
+110,037
New +$2.99M ﹤0.01% 1215

Other funds holding ACRS

UBS AM's ACRS Position: Q3 2026 in Review

UBS AM opened a new position in Aclaris Therapeutics (ACRS) in Q3 2026: 4,267 shares worth $22.4K. The stake represents ﹤0.01% of the portfolio and ranks #3619 among its holdings. This is a return to the name: UBS AM previously reported a position in ACRS as recently as Q4 2023.

UBS AM first reported a position in ACRS in Q2 2017 and has held it in 16 quarters since. The position peaked at $6.03M in Q3 2017. 167 funds tracked by Wall St. Rank hold ACRS as of Q3 2026.

  • UBS AM held 4,267 shares of Aclaris Therapeutics worth $22.4K as of Q3 2026.
  • Aclaris Therapeutics was a new UBS AM position in Q3 2026.
  • Aclaris Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q3 2026, its #3619 holding.
  • UBS AM first reported a position in Aclaris Therapeutics in Q2 2017 and has held it in 16 quarters since.
  • UBS AM's Aclaris Therapeutics position peaked at $6.03M in Q3 2017.
  • 167 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2026.

Based on UBS AM's 13F filing for Q3 2026, filed 16 Nov 2026.